retatrutide triple agonist glp-1 gip glucagon phase 2 trial obesity (LY-3437943) Market Analysis, 2033: Triple-Agonist Therapy Landscape In And Metabolic Disorders Retatrutide (LY3437943), a Novel GIP/GLP-1/Glucagon
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23


























